Science, research, sustainability and equality are our guiding principles and influence all areas of our work. We aim to develop effective treatments that are sustainable for both patients and the wider world.
For Gedea Biotech, sustainability is a core activity – not posturing. According to the World Health Organization (WHO), antibiotic resistance is a growing problem and one of the biggest threats to global public health. Our business concept is to create an antibiotic-free treatment for infections that works for as many people as possible. Clinical trials are currently ongoing and we are gearing up for a product launch. Everything points to pHyph having the potential to make a real impact on a market with a high medical need.
Watch the film about Gedea Biotech, the team and what we are striving for
Annette Säfholm
Annette has a PhD in Medicine from Lund University and holds a Master's degree in Medical Biology from Linköping University. She has long experience of project management and business development in both listed and unlisted companies also from the healthcare sector.
annette.safholm@gedeabiotech.com
+46 (0) 708 - 91 86 81
Eva Norell
Eva has a MSc from Linköping University and has broad experience in medical marketing and project management in the healthcare sector. She has held positions in communication, marketing and sales at Pfizer, Sanofi, Studentlitteratur and within the Swedish Medical Association.
eva.norell@gedeabiotech.com
+46 (0) 709 - 36 04 20
Ekaterina Riabova
Ekaterina has PhD in bioinorganic chemistry from Lund University and a Master’s degree in Chemistry from Moscow State University. Ekaterina has over 10 years of experience in product development, product improvements, vigilance, quality management systems, clinical and regulatory support for new product development projects and global product registrations from several medical device companies. Ekaterina is a certified Quality Auditor ISO 13485, ISO 9001, IVDD/IVDR, MDD/MDR, QSR and MDSAP.
Sten Kornfält
Sten has a Degree of Master of Science in Pharmacy from University of Uppsala. He has held positions as clinical trials manager and project manager for over 25 years. He has extensive experience from developing pharmaceutical products and medical devices.
Olov Sterner
Olov is Professor of Organic Chemistry at Lund University. He has extensive experience in starting and running innovative life science companies. Olov is co-founder of and Chairman of De-NovaStella AB, Board member of PULS (Life Science Partners), Respiratorius AB, Gabather AB and Glactone AB.
Helena Strevens
Helena has a PhD in medicine and a senior consultant in obstetrics and gynecology. As a medical officer, she is responsible for clinical trials and questions regarding the use of the product. Helena has many years of experience in treating vaginal infections and their complications in clinical work. She is also a partner in PULS (Partners for Development Investments in Life Science).
Sophie Manner
Sophie has a PhD in organic chemistry and works as a researcher at Lund University. She is responsible for laboratory research and formulation within Gedea. Sophie is also a partner in PULS (Partners for Development Investments in Life Science).
Ulf Ellervik
Ulf is Professor of Bioorganic Chemistry at Lund University, as well as a founder and member of the board of Molecular Knowledge AB. He is also a partner of PULS (Partners for Development Investments in Life Science).
Ton Berkien
Ton holds a B.Econ from Saxion University of Applied Sciences and a Life Science industry Diploma from PwC / Harvard Business School / IMD. Ton Berkien's expertise is within in leadership, business development and M&A. Since December 2020, he is Chief Business Officer (CBO) at Ultimovacs ASA (Norway). Prior to joining Ultimovacs he was CBO at Nuevolution A/S and Director Global Transactions at Amgen. Further he has experience from, among others, Takeda / Nycomed as Sr. Director of Corporate Development and M&A.
Peter Enberg
Peter Enberg has a Bachelor of Business Administration (BBA) from Lund University. Peter started his career as a trainee and then Product Manager at Unilever. In 1992 he started a company for advertising on shopping charts, with 200 stores in Sweden and 80 employees that worked part time as ad-replacers. In 2004 he and two companions bought out Kung Markatta from Svenska Lantmännen and Peter stayed at Kung Markatta as CEO until 2012. As an investor, Peter has invested in 20 startups and is or has been in the board of eight companies, among them Internatural, Speximo and Accumbo.
Mats Persson
Mats has over 30 years of experience in the marketing and licensing business in the global pharmaceutical industry. Most recently Mats worked for Astellas Pharma, where he has been the General Manager for the Nordic and Baltic countries for the past ten years. He has long experience from senior positions in Novo Nordisk, Pharmacia Corporation and Ferring International.
Per Antonsson
Per has a PhD in Medical Science and holds a Bachelor's Degree in Analytical Chemistry and Biochemistry from Lund University. As Investment Manager at Almi Invest, Per has long experience of business development and investment in start-up companies, preferably in life science. He has had several roles in pharmaceutical and biotechnology companies. Per is currently a board member of two other start-up companies in life science.
Stina Gestrelius
Stina has a PhD in applied biochemistry and has 40 years of experience in research, development, management and board work in Scandinavian life science companies. As an entrepreneur, Stina has worked with research, development, manufacturing and regulatory issues within Biora AB. Stina has also been Vice President of Medicon Valley Alliance and is a member of the Board of Hansa Medical AB (publ).
Game Changer Maj 2017
Crowd Awards September 2017
Mars 2017
The Public´s award 2018
SME Instruments 2019
Fast Track to Innovation 2020
